{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:46:20Z","timestamp":1791359180367,"version":"4.3.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,21]]},"abstract":"<jats:p>In the mid-1990s, the days of lipoprotein(a) [Lp(a)] were numbered and many people would not have placed a bet on this lipid particle making it to the next century. However, genetic studies brought Lp(a) back to the front-stage after a Mendelian randomization approach used for the first time provided strong support for a causal role of high Lp(a) concentrations in cardiovascular disease and later also for aortic valve stenosis. This encouraged the use of therapeutic interventions to lower Lp(a) as well numerous drug developments, although these approaches mainly targeted LDL cholesterol, while the Lp(a)-lowering effect was only a \u2018side-effect\u2019. Several drug developments did show a potent Lp(a)-lowering effect but did not make it to endpoint studies, mainly for safety reasons. Currently, three therapeutic approaches are either already in place or look highly promising: (i) lipid apheresis (specific or unspecific for Lp(a)) markedly decreases Lp(a) concentrations as well as cardiovascular endpoints; (ii) PCSK9 inhibitors which, besides lowering LDL cholesterol also decrease Lp(a) by roughly 30%; and (iii) antisense therapy targeting apolipoprotein(a) which has shown to specifically lower Lp(a) concentrations by up to 90% in phase 1 and 2 trials without influencing other lipids. Until the results of phase 3 outcome studies are available for antisense therapy, we will have to exercise patience, but with optimism since never before have we had the tools we have now to prove Koch\u2019s extrapolated postulate that lowering high Lp(a) concentrations might be protective against cardiovascular disease.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehx033","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T13:27:49Z","timestamp":1485782869000},"page":"1553-1560","source":"Crossref","is-referenced-by-count":173,"title":["Lipoprotein(a): the revenant"],"prefix":"10.1093","volume":"38","author":[{"given":"Baris","family":"Gencer","sequence":"first","affiliation":[{"name":"1Cardiology Division, Geneva University Hospitals, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"2Department of Medical Genetics, Division of Genetic Epidemiology, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Stroes","sequence":"additional","affiliation":[{"name":"3Academic Medical Center, Amsterdam, AZ 1100, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[{"name":"1Cardiology Division, Geneva University Hospitals, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"2022102517401424800_ehx033-B1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102517401424800_ehx033-B2","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102517401424800_ehx033-B3","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2022102517401424800_ehx033-B4","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 esc\/eas guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (esc) and European atherosclerosis society (eas)developed with the special contribution of the European assocciation for cardiovascular prevention & rehabilitation (eacpr)","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102517401424800_ehx033-B5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/eurheartj\/ehv056","article-title":"Sweetless'n low ldl-c targets for pcsk9 treatment","volume":"36","author":"Gencer","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102517401424800_ehx033-B6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Inter Med"},{"key":"2022102517401424800_ehx033-B7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"2022102517401424800_ehx033-B8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102517401424800_ehx033-B9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arteriosclerosis, Thromb Vasc Biol"},{"key":"2022102517401424800_ehx033-B10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1161\/CIRCULATIONAHA.108.789008","article-title":"Impact of inherited thrombophilia on venous thromboembolism in children: A systematic review and meta-analysis of observational studies","volume":"118","author":"Young","year":"2008","journal-title":"Circulation"},{"key":"2022102517401424800_ehx033-B12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2022102517401424800_ehx033-B13","doi-asserted-by":"crossref","first-page":"95.","DOI":"10.1186\/s12944-016-0258-8","article-title":"The relationship between lp(a) and cvd outcomes: a systematic review","volume":"15","author":"Forbes","year":"2016","journal-title":"Lipids Health Dis"},{"key":"2022102517401424800_ehx033-B14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, lpa risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2022102517401424800_ehx033-B15","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"2022102517401424800_ehx033-B16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"2022102517401424800_ehx033-B17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet. Diabete Endocrinol"},{"key":"2022102517401424800_ehx033-B18","first-page":"1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arteriosclerosis Thromb J Vasc Biol\/Am Heart Assoc"},{"key":"2022102517401424800_ehx033-B19","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B21","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B22","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the american heart association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"key":"2022102517401424800_ehx033-B23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of pcsk9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102517401424800_ehx033-B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention","volume":"115","author":"Konishi","year":"2015","journal-title":"Am J Cardiol"},{"key":"2022102517401424800_ehx033-B25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","article-title":"Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention","volume":"205","author":"Konishi","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022102517401424800_ehx033-B26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003012","article-title":"Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (acs)","volume":"5","author":"Afshar","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2022102517401424800_ehx033-B27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102517401424800_ehx033-B29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B31","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"2022102517401424800_ehx033-B32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the jupiter trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"2022102517401424800_ehx033-B33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein b100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2022102517401424800_ehx033-B34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins a-1 and b, and lipoprotein(a) to cardiovascular outcomes: the aim-high trial (atherothrombosis intervention in metabolic syndrome with low hdl\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102517401424800_ehx033-B36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"2022102517401424800_ehx033-B37","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with pcsk9 monoclonal antibody evolocumab (amg 145): a pooled analysis of more than 1,300 patients in 4 phase ii trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102517401424800_ehx033-B38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u2009mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"2022102517401424800_ehx033-B39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40618-016-0433-9","article-title":"Analysis of the association between plasma pcsk9 and lp(a) in han chinese","volume":"39","author":"Yang","year":"2016","journal-title":"J Endocrinol Investig"},{"key":"2022102517401424800_ehx033-B40","first-page":"w14179.","article-title":"Use and role of monoclonal antibodies and other biologics in preventive cardiology","volume":"145","author":"Gencer","year":"2015","journal-title":"Swiss Med Week"},{"key":"2022102517401424800_ehx033-B41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1194\/jlr.R052258","article-title":"Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans","volume":"57","author":"Graham","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102517401424800_ehx033-B42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein b-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase iii trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"2022102517401424800_ehx033-B43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"2022102517401424800_ehx033-B44","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2022102517401424800_ehx033-B45","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Prac Cardiovasc Med"},{"key":"2022102517401424800_ehx033-B46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"2022102517401424800_ehx033-B47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atheroscl Suppl"},{"key":"2022102517401424800_ehx033-B48","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"Hps2-thrive randomized placebo-controlled trial in 25 673 high-risk patients of er niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/20\/1553\/46630685\/eurheartj_38_20_1553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/20\/1553\/46630685\/eurheartj_38_20_1553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T18:28:34Z","timestamp":1666722514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/20\/1553\/3002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":48,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2017,2,17]]},"published-print":{"date-parts":[[2017,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx033","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,21]]},"published":{"date-parts":[[2017,2,17]]}}}